Equities

LAVA Therapeutics NV

LAVA Therapeutics NV

Actions
  • Price (EUR)1.68
  • Today's Change0.04 / 2.44%
  • Shares traded1.00k
  • 1 Year change+36.59%
  • Beta--
Data delayed at least 15 minutes, as of Nov 08 2024 20:55 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments96133133
Total Receivables, Net1.703.250.73
Total Inventory------
Prepaid expenses1.634.412.57
Other current assets, total------
Total current assets99141137
Property, plant & equipment, net2.492.081.95
Goodwill, net------
Intangibles, net------
Long term investments------
Note receivable - long term------
Other long term assets0.320.810.80
Total assets102143139
LIABILITIES
Accounts payable4.453.972.55
Accrued expenses4.297.831.57
Notes payable/short-term debt5.284.640
Current portion long-term debt/capital leases0.440.380.26
Other current liabilities, total0.485.146.87
Total current liabilities152211
Total long term debt0.590.434.60
Total debt6.315.454.87
Deferred income tax------
Minority interest------
Other liabilities, total35355.03
Total liabilities515721
SHAREHOLDERS EQUITY
Common stock3.723.723.65
Additional paid-in capital194194192
Retained earnings (accumulated deficit)(136)(99)(74)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total(11)(13)(4.04)
Total equity5186118
Total liabilities & shareholders' equity102143139
Total common shares outstanding262626
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.